12:40 PM EDT, 09/25/2024 (MT Newswires) -- Celldex Therapeutics ( CLDX ) said new data from a phase 2 study of barzolvolimab demonstrated sustained efficacy in chronic spontaneous urticaria, with most adverse events mild and expected to be reversible.

The company said 71% of patients on barzolvolimab 150 mg Q4W had complete response of no itch or hives at week 52, with improvements seen as early as the first week.

Celldex said barzolvolimab was "well-tolerated" and the most common treatment emergent adverse events observed in more than 10% of the patients taking the drug were hair color changes, neutropenia, urticaria, skin hypopigmentation and nasopharyngitis.

The company said hypopigmentation was noted with longer term exposure, but did not lead to discontinuation of treatment.

Shares of the company were down more than 22% in recent trading.

Price: 31.64, Change: -9.32, Percent Change: -22.75